A Randomized,Double-Blind, Placebo-Controlled, Multicenter, Phase II Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Famitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms HR-FMTN-NSCLC-MON
- Sponsors Jiangsu Hengrui Medicine Co.
- 16 Apr 2018 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2018.
- 16 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Feb 2015 New trial record